Mechanisms of early brain injury after subarachnoid hemmorrhage

蛛网膜下腔出血后早期脑损伤的机制

基本信息

  • 批准号:
    8703823
  • 负责人:
  • 金额:
    $ 33.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-01 至 2017-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Subarachnoid hemorrhage (SAH) is a common subtype of stroke and the mortality rate is high (~35%) in the first several days. The causes of early brain injury following SAH are complicated including brain edema formation, blood-brain barrier disruption, increased intracranial pressure/brief global cerebral ischemia, and neurotoxicity caused by blood components. Research suggests that early brain injury following SAH is a primary therapeutic target. It is well known that the amount of blood released during SAH correlates with neurological deficits and poor clinical outcome. Although hemoglobin has been intensively studied as a potent factor for delayed vasospasm in SAH, the role of hemoglobin and its degradation products (especially iron) in SAH-induced early brain injury is not well studied. Our recent studies have demonstrated: 1) Brain iron overload occurs in a rat model of SAH; 2) Deferoxamine, an iron chelator, reduces SAH-induced iron overload, oxidative stress and mortality; 3) The complement cascade is activated and membrane attack complex levels are increased in the brain after experimental SAH which may play a role in erythrocyte lysis, iron overload and brain injury. However, major gaps in our knowledge regarding complement activation, erythrocyte lysis, brain iron overload and early brain injury after SAH need to be filled. In this application, therefore, we propose to examine the following Specific Aims: 1) To determine whether deferoxamine attenuates SAH-induced brain edema, blood-brain barrier disruption, hydrocephalus and vasospasm, major factors in SAH outcome; 2) To determine whether blocking complement activation reduces erythrocyte lysis, brain iron accumulation and brain injury after SAH. The purpose of our project is to examine mechanisms of early brain injury after SAH. Data from the proposed studies may lead to new therapies for SAH. The long-term goal of our studies is to limit brain damage in SAH patients.
描述(申请人提供):蛛网膜下腔出血(SAH)是中风的一种常见亚型,最初几天的死亡率很高(~35%)。SAH后早期脑损伤的原因很复杂,包括脑水肿形成、血脑屏障破坏、颅内压升高/短暂的全脑缺血以及血液成分引起的神经毒性。研究表明,SAH后的早期脑损伤是主要的治疗目标。众所周知,蛛网膜下腔出血期间释放的血量与神经功能缺失和不良的临床结果相关。虽然血红蛋白作为蛛网膜下腔出血后迟发性血管痉挛的一个重要因素已被广泛研究,但关于血红蛋白及其降解产物(尤其是铁)在蛛网膜下腔出血所致早期脑损伤中的作用尚未得到很好的研究。我们最近的研究表明:1)SAH大鼠模型发生脑铁超载;2)铁络合剂去铁胺可降低SAH引起的铁超载、氧化应激和死亡率;3)实验性SAH后脑内补体级联被激活,膜攻击复合体水平增加,这可能在红细胞溶解、铁超载和脑损伤中起作用。然而,我们在补体激活、红细胞溶解、脑铁超载和SAH后早期脑损伤方面的主要知识空白需要填补。因此,在这一应用中,我们建议检查以下具体目标:1)确定去铁胺是否可以减轻SAH所致的脑水肿、血脑屏障破坏、脑积水和血管痉挛,这些都是SAH预后的主要因素;2)确定阻断补体激活是否减少了SAH后的红细胞溶解、脑铁蓄积和脑损伤。本课题旨在探讨蛛网膜下腔出血后早期脑损伤的机制。来自拟议研究的数据可能会导致SAH的新疗法。我们研究的长期目标是限制SAH患者的脑损伤。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GUOHUA XI其他文献

GUOHUA XI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GUOHUA XI', 18)}}的其他基金

Experimental Cerebral Hemorrhage: Mechanisms and Therapies
实验性脑出血:机制和治疗
  • 批准号:
    9981857
  • 财政年份:
    2020
  • 资助金额:
    $ 33.68万
  • 项目类别:
Experimental Cerebral Hemorrhage: Mechanisms and Therapies
实验性脑出血:机制和治疗
  • 批准号:
    10434649
  • 财政年份:
    2020
  • 资助金额:
    $ 33.68万
  • 项目类别:
Experimental Cerebral Hemorrhage: Mechanisms and Therapies
实验性脑出血:机制和治疗
  • 批准号:
    10609905
  • 财政年份:
    2020
  • 资助金额:
    $ 33.68万
  • 项目类别:
Iron, minocycline and brain injury after intracerebral hemorrhage
铁、米诺环素与脑出血后脑损伤
  • 批准号:
    9450560
  • 财政年份:
    2015
  • 资助金额:
    $ 33.68万
  • 项目类别:
Mechanisms of early brain injury after subarachnoid hemmorrhage
蛛网膜下腔出血后早期脑损伤的机制
  • 批准号:
    8539107
  • 财政年份:
    2012
  • 资助金额:
    $ 33.68万
  • 项目类别:
Mechanisms of early brain injury after subarachnoid hemmorrhage
蛛网膜下腔出血后早期脑损伤的机制
  • 批准号:
    9110333
  • 财政年份:
    2012
  • 资助金额:
    $ 33.68万
  • 项目类别:
Mechanisms of Brain Injury after Intraventricular Hemorrhage
脑室内出血后脑损伤的机制
  • 批准号:
    8292336
  • 财政年份:
    2012
  • 资助金额:
    $ 33.68万
  • 项目类别:
Mechanisms of Brain Injury after Intraventricular Hemorrhage
脑室内出血后脑损伤的机制
  • 批准号:
    8995697
  • 财政年份:
    2012
  • 资助金额:
    $ 33.68万
  • 项目类别:
Mechanisms of early brain injury after subarachnoid hemmorrhage
蛛网膜下腔出血后早期脑损伤的机制
  • 批准号:
    8876826
  • 财政年份:
    2012
  • 资助金额:
    $ 33.68万
  • 项目类别:
Mechanisms of early brain injury after subarachnoid hemmorrhage
蛛网膜下腔出血后早期脑损伤的机制
  • 批准号:
    8410306
  • 财政年份:
    2012
  • 资助金额:
    $ 33.68万
  • 项目类别:

相似海外基金

A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
  • 批准号:
    24K02286
  • 财政年份:
    2024
  • 资助金额:
    $ 33.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    $ 33.68万
  • 项目类别:
    Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    $ 33.68万
  • 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
  • 批准号:
    10742028
  • 财政年份:
    2023
  • 资助金额:
    $ 33.68万
  • 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    $ 33.68万
  • 项目类别:
    Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
  • 批准号:
    LP210301365
  • 财政年份:
    2023
  • 资助金额:
    $ 33.68万
  • 项目类别:
    Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    $ 33.68万
  • 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
  • 批准号:
    10659841
  • 财政年份:
    2023
  • 资助金额:
    $ 33.68万
  • 项目类别:
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
  • 批准号:
    576545-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 33.68万
  • 项目类别:
    Idea to Innovation
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    $ 33.68万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了